LFSPROShiny: An Interactive R/Shiny App for Prediction and Visualization of Cancer Risks in Families With Deleterious Germline TP53 Mutations Among 187 patients identified (median follow-up, 22.4 ...

Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration The concept of time toxicity of cancer treatment, defined as ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Many patients with IBC in LMICs are not receiving TMT. Barriers to diagnosis and treatment were at least partially related to limited providers' comfort level and knowledge, suggesting that ...

Erratum: A Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in a Treatment-Naive CLL Population Enriched for High-Risk Disease Seventy patients were enrolled, 33 (47%) had a ...

Machine Learning to Predict the Individual Risk of Treatment-Relevant Toxicity for Patients With Breast Cancer Undergoing Neoadjuvant Systemic Treatment We analyzed follow-up CT reports from patients ...

Cancer remains a widespread and significant global health issue, with consequential impacts on individuals, families, and societies across the globe. Although there have been noteworthy advancements ...

The Journal of Clinical Oncology podcast, hosted by Dr. Shannon Westin, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of Clinical Oncology.

Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047 In the article that accompanies this editorial, Simon et al 11 and the German CLL Study Group ...

Erratum: Risk Stratification in Older Intensively Treated Patients With AML In this phase II, prospective randomized trial, men (N = 100) with grade group 1 or 2 prostate cancer who elected AS were ...

High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial Nivolumab plus relatlimab demonstrated a statistically ...